Keep container tightly closed in a dry and well-ventilated place. Recommended storage temperature: 2-8°C. Light sensitive

Non-hazardous for transport

Kimura, I., et al., Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine. Arzneimittelforschung 48, 1007-11, (1998); Kumamoto, T., et al., Inhibition by aminosalicylates of lipid peroxidation in large intestinal mucosa after mesenteric ischemia/reperfusion in the rat. Jpn. J. Pharmacol. 75, 187-9, (1997); MacGregor, D.J., et al., Chemoprevention of colon cancer carcinogenesis by balsalazide: inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6-Min/+ mouse. Int. J. Oncol. 17, 173-9, (2000); Simmonds, N.J., et al., Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Aliment. Pharmacol. Ther. 13, 363-72, (1999); Merck 14,945

Balsalazide has antioxidative and anti-inflammatory properties. It inhibits superoxide production and was found to scavenge hypochlorite radicals.¹ Balsalazide was shown to inhibit lipid peroxidation in rat intestinal mucosa.² It was also shown to inhibit azoxymethane-induced colon carcinogenesis.³ In vivo, basalazide is cleaved through azoreduction to produce 4-aminobenzoyl-β-alanine, an inert carrier moiety, and 5-aminosalicylic acid (5-ASA).